Hydrochloric Acid

Hydrochloric Acid

SCHEMBL6231152

N#[N+]c1ncc(CO)s1.[Cl-]

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.33
SRC P12931 1/20 0.31
ZAP70 P43403 1/20 0.31
SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6230455 0.98
SCHEMBL6229873 0.70
SCHEMBL606580 0.67
SCHEMBL281998 0.67
SCHEMBL2956791 0.67
SCHEMBL6234352 0.67
SCHEMBL12289411 0.66
SCHEMBL2643645 0.66
SCHEMBL2644167 0.66
SCHEMBL2644166 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1626525-A Process for the preparation of thiazole derivatives SYNGENTA CROP PROT INC (CH) 2005-06-15 CN disclosed
EP-1202979-B1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2005-04-27 EP disclosed
EP-1313747-B1 METHOD FOR PRODUCING ALKYL-BRIDGED LIGAND SYSTEMS AND TRANSITION METAL COMPOUNDS BASELL POLYOLEFINE GMBH (DE) 2005-04-20 EP disclosed
CN-1169800-C Process for preparing thiazole derivatives �����ɷ� 2004-10-06 CN disclosed
US-6710182-B2 REACTING 5-HYDROXYMETHYLTHIAZOLE-DIAZONIUM SALT WITH HYDROGEN HALIDE OR MINERAL ACID; CHLORINATION, DESALTING, DEHYDROXYLATION SYNGENTA CROP PROTECTION, INC. 2004-03-23 US disclosed
US-20030191321-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES COPPOLA KEVIN (US) 2003-10-09 US disclosed
US-6566530-B2 Preparing 2-chloro-5-chloromethylthiazole by reacting 2-hydroxy-5-hydroxymethylthiazole with a chloride anion source in the presence of an acid. SYNGENTA CROP PROTECTION, INC. 2003-05-20 US disclosed
US-20030055229-A1 Process for the preparation of thiazole derivatives COPPOLA KEVIN (US) 2003-03-20 US disclosed
US-6476230-B1 Process for the preparation of thiazole derivatives SYNGENTA CROP PROTECTION, INC. 2002-11-05 US disclosed
CN-1368966-A Process for preparing thiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2002-09-11 CN disclosed
EP-1202979-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2002-05-08 EP disclosed
US-6265553-B1 INTERMEDIATES FOR INSECTICIDES SYNGENTA CROP PROTECTION, INC. 2001-07-24 US disclosed
WO-2001010852-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2001-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055229-A1 Process for the preparation of thiazole derivatives DDT, CYP3A5, CYP3A4 CYP2A6 57/4885SRC 1958/4885ZAP70 1991/4885
US-20030191321-A1 PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES DDT, CYP3A5, CYP3A4 CYP2A6 57/4885SRC 1958/4885ZAP70 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.